Market Cap 573.15B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.08
Forward PE 20.64
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 6,422,429
Avg Vol 8,317,262
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 49%
Beta 0.34
Analysts Strong Sell
Price Target $243.96

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
frb1985
frb1985 Apr. 15 at 9:39 PM
$JNJ a lot great new highs. LOL
0 · Reply
focafoca99
focafoca99 Apr. 15 at 9:13 PM
$JNJ to participate in the Bank of America 2026 Healthcare Conference https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-participate-66bd83
0 · Reply
Bazzzigar
Bazzzigar Apr. 15 at 6:22 PM
$JNJ NVO
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 15 at 6:15 PM
$JNJ is correcting lower in 3 swing towards 229.32 - 219.31 area where buyers are expected to come in again. For more details link here 👉 https://elliottwave-forecast.com/stock-market/jnj-stock-extended-rally-signals-buyers/ Trade Blue Box #Trading #Elliottwave #stockmarkets
0 · Reply
IN0V8
IN0V8 Apr. 15 at 4:18 PM
$JNJ Bernstein raises target price to $251 from $225 Leerink Partners raises target price to $252 from $232 Morgan Stanley raises target price to $283 from $267 Raymond James raises target price to $258 from $237 RBC raises target price to $265 from $255 Stifel raises target price to $250 from $220 Wells Fargo raises target price to $263 from $240
0 · Reply
trenddetector
trenddetector Apr. 15 at 2:27 PM
$MRK $JNJ $GILD I built the tool I wish I had 16 years ago. If you or a loved one is facing a diagnosis, don't navigate it in the dark. www.YourCancerPath.com is a free, anonymous way to map out diagnostic steps and find live clinical trials without the medical jargon. Pass it on—it could be a lifeline for someone today.
0 · Reply
peloswing
peloswing Apr. 15 at 12:42 PM
$JNJ has been flagging recently, after going on a 71% run between the end of June 2025 and beginning of March of this year. - Johnson & Johnson reported earnings yesterday (EPS of $2.70 > Exp. $2.67 & Sales of $24.06B > Exp. $23.61B) ✅ - Raised 2026 sales guidance to ~$100.8B and adj. EPS to ~$11.55. Dividend increased ⬆️ - Has potential for about a month's worth of chop before it reaches the apex of this triangulation and should have a nice directional breakout.
0 · Reply
Quantumup
Quantumup Apr. 15 at 12:33 PM
H.C. Wainwright reiterated $ALMS Buy; $25 after H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference. $JNJ - $PTGX ORKA TAK BMY ABBV NVS LLY H.C. Wainwright said in its note: Per our Inflammatory Skin Disease Conference yesterday, our most important takeaways from the fireside chat with Alumis management were as follows: (1) envu may be the strongest oral TYK2, given the baseline characteristics and comparability between envu trials, (2) response may still deepen beyond Week 24, (3) twice-daily (BID) dosing is expected to be a temporary launch format (with QD on the way), and (4) differentiators from competition could be itch relief, quality of life, and prescribing simplicity (with simplicity strategy yet to be unveiled). We reiterate our Buy rating and 12-month price target of $25.
0 · Reply
StockMacroView
StockMacroView Apr. 15 at 7:44 AM
$PG and $JNJ had disappointing dividend increases. I’m not selling, but I’m curious if this is the emerging trend for the year among the Dividend Kings. 👉Click to view @StockMacroView for timely updates amid the volatility.
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Apr. 15 at 1:41 AM
$JNJ would love to see this go higher!!
0 · Reply
Latest News on JNJ
J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 1 day ago

J&J raises guidance for 2026 on strong start to the year


J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 1 day ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength


The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 27 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX


US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 4 weeks ago

US FDA approves J&J's oral psoriasis pill


US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 5 weeks ago

US FDA approves JNJ's blood cancer drug


Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 7 weeks ago

Does JNJ Stock Still Offer Value?


Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 7 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech


frb1985
frb1985 Apr. 15 at 9:39 PM
$JNJ a lot great new highs. LOL
0 · Reply
focafoca99
focafoca99 Apr. 15 at 9:13 PM
$JNJ to participate in the Bank of America 2026 Healthcare Conference https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-participate-66bd83
0 · Reply
Bazzzigar
Bazzzigar Apr. 15 at 6:22 PM
$JNJ NVO
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 15 at 6:15 PM
$JNJ is correcting lower in 3 swing towards 229.32 - 219.31 area where buyers are expected to come in again. For more details link here 👉 https://elliottwave-forecast.com/stock-market/jnj-stock-extended-rally-signals-buyers/ Trade Blue Box #Trading #Elliottwave #stockmarkets
0 · Reply
IN0V8
IN0V8 Apr. 15 at 4:18 PM
$JNJ Bernstein raises target price to $251 from $225 Leerink Partners raises target price to $252 from $232 Morgan Stanley raises target price to $283 from $267 Raymond James raises target price to $258 from $237 RBC raises target price to $265 from $255 Stifel raises target price to $250 from $220 Wells Fargo raises target price to $263 from $240
0 · Reply
trenddetector
trenddetector Apr. 15 at 2:27 PM
$MRK $JNJ $GILD I built the tool I wish I had 16 years ago. If you or a loved one is facing a diagnosis, don't navigate it in the dark. www.YourCancerPath.com is a free, anonymous way to map out diagnostic steps and find live clinical trials without the medical jargon. Pass it on—it could be a lifeline for someone today.
0 · Reply
peloswing
peloswing Apr. 15 at 12:42 PM
$JNJ has been flagging recently, after going on a 71% run between the end of June 2025 and beginning of March of this year. - Johnson & Johnson reported earnings yesterday (EPS of $2.70 > Exp. $2.67 & Sales of $24.06B > Exp. $23.61B) ✅ - Raised 2026 sales guidance to ~$100.8B and adj. EPS to ~$11.55. Dividend increased ⬆️ - Has potential for about a month's worth of chop before it reaches the apex of this triangulation and should have a nice directional breakout.
0 · Reply
Quantumup
Quantumup Apr. 15 at 12:33 PM
H.C. Wainwright reiterated $ALMS Buy; $25 after H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference. $JNJ - $PTGX ORKA TAK BMY ABBV NVS LLY H.C. Wainwright said in its note: Per our Inflammatory Skin Disease Conference yesterday, our most important takeaways from the fireside chat with Alumis management were as follows: (1) envu may be the strongest oral TYK2, given the baseline characteristics and comparability between envu trials, (2) response may still deepen beyond Week 24, (3) twice-daily (BID) dosing is expected to be a temporary launch format (with QD on the way), and (4) differentiators from competition could be itch relief, quality of life, and prescribing simplicity (with simplicity strategy yet to be unveiled). We reiterate our Buy rating and 12-month price target of $25.
0 · Reply
StockMacroView
StockMacroView Apr. 15 at 7:44 AM
$PG and $JNJ had disappointing dividend increases. I’m not selling, but I’m curious if this is the emerging trend for the year among the Dividend Kings. 👉Click to view @StockMacroView for timely updates amid the volatility.
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Apr. 15 at 1:41 AM
$JNJ would love to see this go higher!!
0 · Reply
Suite510
Suite510 Apr. 15 at 12:00 AM
$JNJ $KVUE $ABT All still have baby rash 🤣🥃🥳 wow 😮 big day junk n junk you finish up what 1% 😆
0 · Reply
Estimize
Estimize Apr. 14 at 8:50 PM
$JNJ reported 2.70 EPS and 24,062 revenue for Q1. http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_content=JNJ&utm_me
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Apr. 14 at 6:44 PM
$JNJ $KVUE $SPX $SPY @Suite510 is a complete moron. He’s been spamming about legal issues since $150. Dipshit has zero investment knowledge.
1 · Reply
yellowstar16
yellowstar16 Apr. 14 at 6:21 PM
$JNJ Large positions here . Happy with another Divy increase and YTD performance. Holding Long.
0 · Reply
HydrogenH2
HydrogenH2 Apr. 14 at 5:58 PM
$JNJ Here why...
0 · Reply
Pearl_Power
Pearl_Power Apr. 14 at 5:44 PM
$JNJ might be time $XLV
0 · Reply
HydrogenH2
HydrogenH2 Apr. 14 at 5:43 PM
$JNJ I'm taking some more profits... bring some $$$ to Telcos a little !!
0 · Reply
maikl_211
maikl_211 Apr. 14 at 5:04 PM
0 · Reply
Smikell9
Smikell9 Apr. 14 at 4:47 PM
0 · Reply
trenddetector
trenddetector Apr. 14 at 2:47 PM
$JNJ LOST IN A CANCER DIAGNOSIS? You don’t have to be a doctor to understand your treatment options. Your Cancer Path is a free, local-born resource that translates complex medical jargon into plain English. Find every FDA-approved treatment. Search live clinical trials (updated daily). Follow a step-by-step diagnostic guide. 100% Free. 100% Anonymous. No account needed. Start your path at: www.yourcancerpath.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 1:59 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $240.00 | Type: CALL Option Plan (premium): Entry: $3.25 Stop: $2.34 TP1: $4.23 TP2: $5.52 TP3: $7.80 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
Skimman
Skimman Apr. 14 at 1:43 PM
$JNJ Company killing it.. stock does this shit
1 · Reply